Equities Analysts Offer Predictions for YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Cantor Fitzgerald issued their FY2025 EPS estimates for Y-mAbs Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($0.67) per share for the year. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

Several other equities research analysts have also recently weighed in on YMAB. Oppenheimer assumed coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $6.28 on Wednesday. Y-mAbs Therapeutics has a 1 year low of $6.01 and a 1 year high of $20.90. The stock has a market capitalization of $281.28 million, a PE ratio of -11.63 and a beta of 0.69. The business’s 50-day moving average is $8.85 and its 200 day moving average is $11.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same period last year, the business earned ($0.18) EPS.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently modified their holdings of YMAB. SG Americas Securities LLC increased its stake in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after acquiring an additional 4,163 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after purchasing an additional 2,854 shares during the period. Principal Financial Group Inc. bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $267,000. Barclays PLC lifted its holdings in shares of Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after purchasing an additional 56,244 shares during the last quarter. Finally, Empire Financial Management Company LLC bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth approximately $210,000. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.